The Adaptive Immune Response to Epstein-Barr virus.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1017834

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Epstein-Barr virus (EBV), the causative agent of glandular fever, is carried by a large proportion of adults worldwide. EBV is known to cause many cancers including Burkitt's lymphoma and has been linked to autoimmune diseases such as multiple sclerosis. The aim of this project is to find new fragments of EBV that the body's immune system can recognise and use to protect itself against the virus. Once found these pieces will form parts of the puzzle that will one day combine as a vaccine against EBV.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2014

Funding Scheme: Postgraduate Scholarships

Funding Amount: $92,314.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cellular Immunology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

T cell epitope | T cell receptor | cancer prevention | cell culture | cellular immunology | immune system disorder | virus eradication

Related Links